IN8bio Q3 2026 earnings: net loss widens to $4.59M

IN8bio remains on track to report initial in vivo preclinical data for INB-619 by year-end 2026.

Available on EDGAR 11/05/2026 - 04:10 PM EST Accepted by SEC EDGAR 11/05/2026 - 04:10 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

IN8bio (INAB) reported a third-quarter 2026 net loss of $4.592 million, compared with $3.854 million in the prior-year quarter. Research and development expense was $2.599 million versus $2.104 million, primarily reflecting preclinical costs for its T-cell engager platform; general and administrative expense was $2.122 million versus $1.863 million. For the first nine months, net loss was $14.463 million, compared with $14.498 million in 2025. Cash was $13.973 million as of September 30, 2026, compared with $27.092 million as of December 31, 2025.

Oxana Polyakova, Ph.D., joined as Senior Vice President of Research & Development in September 2026. IN8bio said it remains on track to report initial in vivo preclinical data for INB-619 by year-end 2026; the candidate is being studied for potential applications in oncology and autoimmune diseases. An October 2026 Nature Reviews Drug Discovery review noted INB-619's ability to activate and expand tissue-resident Vδ1 and circulating Vδ2 γδ T cells in vitro. Phase 1 data for INB-200 in newly diagnosed glioblastoma were published in the Journal of Clinical Oncology in July 2026.

0 points · 0 major

NegativeiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 1 point

How the balance works

Positive

• None.

Negative

• Major pointQuarterly net loss rose to $4.592 million from $3.854 million a year earlier.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Net loss: $4.592 million Research and development expense: $2.599 million General and administrative expense: $2.122 million +2 more

5 metrics

Net loss $4.592 million Three months ended September 30, 2026; $3.854 million in the comparable 2025 period

Research and development expense $2.599 million Three months ended September 30, 2026; $2.104 million in the comparable 2025 period

General and administrative expense $2.122 million Three months ended September 30, 2026; $1.863 million in the comparable 2025 period

Net loss per basic and diluted common share $0.24 Three months ended September 30, 2026; $0.85 in the comparable 2025 period

Cash $13.973 million As of September 30, 2026

Key Terms

γδ T cells, T cell engagers (TCEs), in vivo, haploidentical stem cell transplantation

4 terms

γδ T cells medical

"developing γδ T cell therapies and T cell engagers"

A small subset of T lymphocytes that carry a distinct gamma-delta (γδ) T-cell receptor and act as a rapid-response link between the body’s immediate, non-specific defenses and its slower, targeted immune response. Like a neighborhood watch that can both spot unusual activity and call in specialists, they can quickly recognize stressed, infected, or tumor cells and influence inflammation and immune memory, making them a target or biomarker in drug development, clinical trials, and regulatory assessments that affect biotech valuation.

T cell engagers (TCEs) medical

"T cell engagers (TCEs) for cancer and autoimmune diseases"

T cell engagers are a class of engineered drugs that act like a molecular bridge, binding a patient’s T cells on one side and disease cells (often cancer cells) on the other to force the immune system to kill the targeted cells. They matter to investors because successful T‑cell engager programs can produce highly effective, high‑value therapies but carry significant clinical, regulatory and manufacturing risks, so trial results, approvals and scale-up directly influence a company’s value.

in vivo technical

"initial in vivo preclinical data for INB-619"

In vivo describes tests or experiments performed inside a living organism, such as an animal or human, to observe how a drug, device or biological process behaves in a real, functioning body. Investors care because in vivo results reveal safety, effectiveness and possible side effects that lab tests cannot, much like road-testing a prototype car in traffic rather than only on a bench — outcomes can strongly influence regulatory approval, clinical success and a company’s valuation.

haploidentical stem cell transplantation medical

"undergoing haploidentical stem cell transplantation"

Earnings Snapshot

Net loss: $4.592 million

Three months ended September 30, 2026

Net loss $4.592 million Compared with $3.854 million in the comparable 2025 period.

Research and development expense $2.599 million Compared with $2.104 million in the comparable 2025 period.

General and administrative expense $2.122 million Compared with $1.863 million in the comparable 2025 period.

Net loss per basic and diluted common share $0.24 Compared with $0.85 in the comparable 2025 period.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was INAB's net loss in the third quarter of 2026?

IN8bio reported a net loss of $4.592 million for the three months ended September 30, 2026, compared with $3.854 million in the comparable 2025 period.

Who joined IN8bio as Senior Vice President of Research & Development?

Oxana Polyakova, Ph.D., joined IN8bio as Senior Vice President of Research & Development in September 2026. She previously served as chief scientific officer at LAVA Therapeutics and LIfT Biosciences and was scientific founder and head of discovery at Adaptate Biotherapeutics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000174027900017402792026-11-052026-11-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 05, 2026

IN8bio, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39692	82-5462585
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
350 5th Avenue, Suite 5330
New York, New York				10118
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 646 600-6438

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		INAB		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 5, 2026, IN8bio, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated November 5, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		IN8bio, Inc.
Date:	November 5, 2026	By:	/s/ Patrick McCall
			Patrick McCall
			Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)

Exhibit 99.1

IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights

•Strengthened research and development (R&D) leadership by appointing Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development

•Received third-party recognition of INB-619 in a Nature Reviews Drug Discovery review of next-generation immune cell engagers for autoimmune disease

•Remain on track to report initial in vivo (animal) data for INB-619 by year-end 2026

NEW YORK, Nov. 5, 2026 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today reported financial results and business highlights for the third quarter ended September 30, 2026.

“This quarter we continued to build upon our deep expertise in γδ T cells, officially welcoming Dr. Polyakova to the team and making progress with our proprietary TCE platform,” said William Ho, CEO and co-founder of IN8bio. “It’s also exciting to see the external recognition that the unique properties of γδ T cells and their tissue-specific distribution, “may offer a unique opportunity to eliminate pathogenic cells more precisely and deeply in target organs” as stated in the Nature Reviews article. We believe this platform has the potential to enable a new class of therapeutics for autoimmune diseases and oncology, and we are excited to present our initial animal data by year-end.”

Third Quarter 2026 Business Highlights

Strengthened Research and Development Leadership

•Oxana Polyakova, Ph.D., joined IN8bio as Senior Vice President of Research & Development in September 2026, bringing 20 years of experience in γδ T cell biology, immunology, oncology, TCE and biologics development.

•Dr. Polyakova joins IN8bio from LAVA Therapeutics, a clinical-stage immuno-oncology company developing bispecific γδ T cell engagers, where she served as Chief Scientific Officer (CSO). She previously also served as CSO at LIfT Biosciences. She was Scientific Founder and Head of Discovery at Adaptate Biotherapeutics, a γδ TCE focused spinout of GammaDelta Therapeutics, which was acquired by Takeda. At Adaptate, she designed and led its R&D strategy, established its laboratories and built its R&D team which has a

program currently in the clinic. Dr. Polyakova served as the Protein and Molecular Leader at GammaDelta Therapeutics Limited that was also acquired by Takeda.

•She will help lead R&D efforts to accelerate IN8bio's γδ TCE pipeline toward clinical development.

Publication of INB-200 Phase 1 Data in GBM

•In July 2026, IN8bio announced the publication of peer-reviewed clinical data from the Phase 1 trial of INB-200 (DeltEx™ DRI) in patients with newly diagnosed GBM in the Journal of Clinical Oncology(JCO), titled “Intracranial injection of ex vivo expanded and activated gamma-delta T cells engineered with a MGMT-expressing lentivector in patients with primary glioblastoma.”

Advancing γδ T Cell Engager Platform (INB-619)

•Continued advancing proprietary INB-600 platform of novel pan-γδ TCEs designed to selectively engage and expand γδ T cells to eliminate disease-associated target cells while potentially improving tolerability compared with conventional CD3-targeting TCEs.

•Advancing INB-619 through preclinical studies for potential applications in oncology and autoimmune diseases.

•INB-619 was included in a review of next-generation immune cell engagers for B cell depletion in autoimmune disease published in Nature Reviews Drug Discovery in October 2026, which noted its ability to activate and expand both tissue-resident Vδ1 and circulating Vδ2 γδ T cells in vitro.

•Remain on track to report initial in vivo preclinical data for INB-619 by year-end 2026.

Third Quarter 2026 Financial Highlights

•Research and Development (R&D) expenses: R&D expenses were $2.6 million for the three months ended September 30, 2026, compared with $2.1 million for the comparable prior year period. This amount includes non-cash items such as stock-based compensation (SBC) and depreciation of $0.4 million for the three months ended September 30, 2026. The increase was due primarily to preclinical costs associated with the Company’s T cell engager platform.

•General and administrative (G&A) expenses: G&A expenses were $2.1 million for the three months ended September 30, 2026, compared with $1.9 million for the comparable prior year period. This amount includes non-cash items such as SBC and depreciation of $0.3 million for the three months ended September 30, 2026. The increase was due primarily to higher spending on professional services.

•Net loss: The Company reported a net loss of $4.6 million, or $0.24 per basic and diluted common share, for the three months ended September 30, 2026, compared with a net loss of $3.9 million, or $0.85 per basic and diluted common share, for the comparable prior year period.

•Cash position: As of September 30, 2026, the Company had cash of $14.0 million, compared with $10.7 million as of September 30, 2025.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also developing INB-100, an allogeneic γδ T cell therapy candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell therapy candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.in8bio.com.

Forward Looking Statements

This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential of IN8bio’s product candidates; the potential of IN8bio’s INB-600 platform to improve durability and safety compared with traditional CD3-targeting engagers; IN8bio’s ability to achieve anticipated milestones, including receipt of guidance from the FDA on regulatory pathways for the DeltEx™ DRI GBM program, expected presentations and data readouts from its preclinical studies and clinical trials including preclinical in vivo data for INB-619, patient dosing timelines and advancement of clinical development plans; and other statements that are not historical fact. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio’s ability to meet anticipated deadlines and milestones; uncertainties inherent in

the initiation and completion of preclinical studies and clinical trials and clinical development of IN8bio’s product candidates; the risk that IN8bio may be unable to raise additional capital and could be forced to delay, further reduce or to explore other strategic options for certain of its development programs, or even terminate its operations; IN8bio’s ability to continue to operate as a going concern; the risk that IN8bio may not realize the intended benefits of its DeltEx platform and TCE program; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio’s product candidates; the uncertainty of regulatory approvals to conduct trials or to market products; IN8bio’s reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause IN8bio’s actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section entitled “Risk Factors” in IN8bio’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on August 6, 2026, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

Investors and Corporate Contact:

IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@in8bio.com

Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

IN8BIO, INC.

BALANCE SHEETS

(In thousands, except share and per share data)

		September 30,
		2026				December 31,
		(unaudited)				2025
Assets						(Note 2)
Current assets
Cash		$	13,973			$	27,092
Prepaid expenses and other current assets			1,221				788
Total Current Assets			15,194				27,880
Non-current assets
Property and equipment, net			1,342				1,858
Restricted cash			177				220
Right-of-use assets - finance leases			64				296
Right-of-use assets - operating leases			1,816				1,882
Other non-current assets			102				146
Total Non-Current Assets			3,501				4,402
Total Assets		$	18,695			$	32,282
Liabilities and Stockholders' Equity
Liabilities
Current liabilities
Accounts payable		$	493			$	309
Accrued expenses and other current liabilities			1,278				1,633
Short-term finance lease liability			64				295
Short-term operating lease liability			793				924
Total Current Liabilities			2,628				3,161
Long-term operating lease liability			1,893				1,563
Total Non-Current Liabilities			1,893				1,563
Total Liabilities			4,521				4,724
Stockholders' Equity
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; no shares issued and outstanding			—				—
Common stock, par value $0.0001 per share; 490,000,000 shares authorized at September 30, 2026 and December 31, 2025; 9,858,383 and 9,766,132 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively			10				10
Additional paid-in capital			169,723				168,644
Accumulated deficit			(155,559	)			(141,096	)
Total Stockholders' Equity			14,174				27,558
Total Liabilities and Stockholders' Equity		$	18,695			$	32,282

IN8BIO, INC.

STATEMENTS OF OPERATIONS

(In thousands, except share and per share data)

		Three Months Ended September 30,								Nine Months Ended September 30,
		2026				2025				2026				2025
Operating expenses:
Research and development		$	2,599			$	2,104			$	7,705			$	7,563
General and administrative			2,122				1,863				7,217				7,265
Total operating expenses			4,721				3,967				14,922				14,828
Interest income			129				113				459				330
Loss from operations			(4,592	)			(3,854	)			(14,463	)			(14,498	)
Net loss		$	(4,592	)		$	(3,854	)		$	(14,463	)		$	(14,498	)
Net loss per share – basic and diluted		$	(0.24	)		$	(0.85	)		$	(0.74	)		$	(4.18	)
Weighted-average number of shares used in computing net loss per common share, basic and diluted			19,473,123				4,537,683				19,471,400				3,465,257

# # #

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 231.7 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 25.4 KB